New York, NY -- (ReleaseWire) -- 03/15/2013 -- Sinovac Biotech Ltd. (NASDAQ: SVA) announced preliminary top-line data from its Phase III clinical trial assessing the efficacy, immunogenicity and safety of the Company's proprietary Enterovirus 71 vaccine against hand, foot and mouth disease.
The primary objective of the study was to evaluate the efficacy of the EV71 vaccine in the prevention of HFMD caused by EV71 in infants of 6 to 35 months old. The preliminary Phase III data showed that Sinovac's EV71 vaccine was 95.4% (95% CI: 87.5%, 98.3%) efficacious against HFMD caused by EV71.
The double-blinded, randomized, placebo controlled Phase III clinical trial was conducted at three sites across China's Jiangsu province.
Find out where SVA could be headed by getting the free and full trend analysis report here: http://www.wallstreetscoop.net/market-scan/?symbol=SVA
Rite Aid Corporation (NYSE: RAD) recently announced sales results for February. For the five weeks ended March 2, 2013, same store sales decreased 3.6 percent over the prior-year period.
February front-end same store sales decreased 1.3 percent while February front-end same store sales attributable to flu-related over-the-counter products were flat.
Pharmacy same store sales, which included an approximate 695 basis points negative impact from new generic introductions, decreased 4.7 percent. Prescription count at comparable stores increased 0.3 percent over the prior-year period. This number includes a decrease of 0.1 percent attributable to flu-related prescriptions and flu shots.
Rite Aid Corporation, through its subsidiaries, operates retail drugstores in the United States.
Get the latest news on RAD by getting the free and full trend analysis report here: http://www.wallstreetscoop.net/market-scan/?symbol=RAD
WallStreetScoop.net issues momentum alerts on stocks that can provide gains to day traders and short-term investors. WallStreetScoop.net provides members with timely information and exclusive alerts on under-valued stocks in the United States with the potential to deliver short-term gains.
WallStreetScoop.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetScoop.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading small cap stocks. Gain an Edge by joining the WallStreetScoop.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Scoop believes traders should have a chance at successfully trading Small stocks and invites traders and investors to be part of the free membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetScoop.net
WallStreetScoop.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetScoop.Net website, for complete risks and disclosures.
Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
For full disclaimer visit: http://www.wallstreetscoop.net/disclaimer/
Wall Street Scoop